Qiaojing Eastern Investment

Qiaojing Eastern Investment operates as a venture capital firm, focusing its capital deployment primarily into Series C funding rounds. The firm specifically targets investments within the healthcare, pharmaceutical, and biotechnology sectors. It provides essential growth capital to later-stage companies that demonstrate significant market potential and an established operational foundation.

Established in 2013 and based in Shanghai, China, the firm's inception stemmed from a recognition of the growing demand for significant late-stage funding in specific high-growth industries. This insight drove the firm to support companies ready to scale beyond their initial developmental phases into broader market expansion.

The firm's portfolio comprises innovative companies throughout East Asia that require substantial capital for market expansion and strategic development. Qiaojing Eastern Investment generally acts as a follow-on investor, supporting existing funding rounds rather than leading them. Its vision is to facilitate the advancement of key industries by empowering high-potential enterprises in the region.